Literature DB >> 17889716

Myelodysplastic syndrome accompanied by basophilia and eosinophilia with t(5;12)(q31;p13).

Yukitaka Katsura, Kazumi Suzukawa, Toru Nanmoku, Noriko Nemoto, Takayuki Machino, Naoshi Obara, Yasushi Okoshi, Harumi Yamamoto Mukai, Yuichi Hasegawa, Hiroshi Kojima, Yasushi Kawakami, Toshiro Nagasawa.   

Abstract

Entities:  

Mesh：

Year:  2007        PMID： 17889716     DOI： 10.1016/j.cancergencyto.2007.05.020

Source DB:  PubMed          Journal:  Cancer Genet Cytogenet        ISSN： 0165-4608


× No keyword cloud information.
  5 in total

Review 1.  Therapy-related acute myeloid leukemia with eosinophilia, basophilia, t(4;14)(q12;q24) and PDGFRA rearrangement: a case report and review of the literature.

Authors:  Jun Zhou; Peter Papenhausen; Haipeng Shao
Journal:  Int J Clin Exp Pathol       Date:  2015-05-01

2.  A Novel IL3-ETV6 Fusion in Chronic Eosinophilic Leukemia Not Otherwise Specified With t(5; 12) (q31; p13): A Case Report and Literature Review.

Authors:  Cenzhu Zhao; Man Wang; Yuchen Zhan; Yang Xu; Suning Chen; Qinrong Wang; Jingnan An; Tianhui Liu
Journal:  Front Oncol       Date:  2022-06-07       Impact factor: 5.738

3.  Chronic eosinophilic leukemia, NOS with t(5;12)(q31;p13)/ETV6-ACSL6 gene fusion: a novel variant of myeloid proliferative neoplasm with eosinophilia.

Authors:  Ruijun Jeanna Su; Brian A Jonas; Jeanna Welborn; Jeffrey Paul Gregg; Mingyi Chen
Journal:  Hum Pathol (N Y)       Date:  2016-09

4.  Myeloid Neoplasms with t(5;12) and ETV6-ACSL6 Gene Fusion, Potential Mimickers of Myeloid Neoplasm with PDGFRB Rearrangement: Case Report with Imatinib Therapy and Review of the Literature.

Authors:  Javier De Luca-Johnson; Jose I Ruades Ninfea; Lauren Pearson; Joanna Conant; Ronald Bryant; Neil A Zakai; Mary E Tang
Journal:  Case Rep Med       Date:  2016-09-26

5.  ETV6-ACSL6 fusion gene in myeloid neoplasms: clinical spectrum, current practice, and outcomes.

Authors:  Xia Wu; Hao Cai; Yu Qiu; Jian Li; Dao-Bin Zhou; Xin-Xin Cao
Journal:  Orphanet J Rare Dis       Date:  2020-07-28       Impact factor: 4.123
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.